Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Transfert Plus Limited Partnership is active in the Biotechnology & Pharmaceuticals technology area, where it currently has 1 pending office action. This single case is being reviewed by 1 distinct examiner, CHERNYSHEV, OLGA N, who provides the primary evaluation of the company's technical claims. With only 1 pending office action, the company can focus its legal strategy on the specific feedback and requirements of this examiner. This concentrated approach is often more efficient than managing multiple concurrent applications across different examiners and art units.
The company's current prosecution activity is situated within 1 distinct art unit, which helps maintain a consistent technical focus for its patent efforts. CHERNYSHEV, OLGA N is identified as the busiest examiner for this portfolio, with 1 busiest examiner pending action currently on her docket. Since this is the only 1 pending office action in the portfolio, the company's entire strategy at the USPTO is currently centered on this interaction. This lack of complexity across multiple examiners or 1 distinct art unit simplifies the management of the patent portfolio and allows for a more focused legal approach.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHERNYSHEV, OLGA N | 1 | 54.5% | +34.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18567915 | COMBINATION THERAPY FOR THE TREATMENT OF ENTERIC NEUROPATHIES | CHERNYSHEV, OLGA N | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18567915 | COMBINATION THERAPY FOR THE TREATMENT OF ENTERIC NEUROPATHIES | CHERNYSHEV, OLGA N | 1675 | §103DP | Non-Final OA | — | Pending | Dec 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTransfert Plus Limited Partnership has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Olga N Chernyshev has the most, with 1 of Transfert Plus Limited Partnership's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
